Sanofi (EPA:SAN) Stock Price Crosses Above Two Hundred Day Moving Average of $0.00

Sanofi SA (EPA:SAN) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.00 and traded as high as $83.38. Sanofi shares last traded at $81.68, with a volume of 1,460,912 shares trading hands.

SAN has been the topic of several analyst reports. Goldman Sachs Group set a €81.00 ($94.19) price objective on Sanofi and gave the company a “neutral” rating in a research note on Monday, November 4th. Credit Suisse Group set a €94.00 ($109.30) price objective on Sanofi and gave the company a “buy” rating in a research note on Friday, November 1st. Barclays set a €80.00 ($93.02) price objective on Sanofi and gave the company a “neutral” rating in a research note on Thursday, October 31st. Morgan Stanley set a €90.00 ($104.65) price objective on Sanofi and gave the company a “buy” rating in a research note on Monday, September 23rd. Finally, JPMorgan Chase & Co. set a €81.00 ($94.19) price objective on Sanofi and gave the company a “neutral” rating in a research note on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of €89.12 ($103.62).

The stock’s 50 day simple moving average is €82.88.

Sanofi Company Profile (EPA:SAN)

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Recommended Story: Discount Rate

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.